About Charles

Charles Gore was diagnosed with hepatitis C in 1995 and cirrhosis in 1998. In 2000 he set up The Hepatitis C Trust together with 3 friends who also had hepatitis C. In 2002 he did pegylated interferon and ribavirin treatment and successfully eradicated the virus.

He has continued to run the Trust, working extensively with Government Departments and the National Health Service (NHS) in the UK, championing the patient perspective. He was closely involved in the creation of the European Liver Patients Association and was elected its first President in 2004. In 2007 he organised a meeting of hepatitis patient organisations from around the world to agree on co-ordinated global action. From this emerged the decision to hold an annual World Hepatitis Day and to create a new NGO, the World Hepatitis Alliance, of which Charles is the President. As a result of advocacy by the Alliance and its members WHO adopted successive viral hepatitis resolutions in 2010 and 2014, making World Hepatitis Day an official day and mandating the creation of a global strategy to tackle viral hepatitis.

Charles sits on a number of national and international advisory bodies including various WHO hepatitis guidelines development groups and the WHO Director-General’s Strategic and Technical Advisory Committee for Viral Hepatitis.

This speaker will be presenting at the following session(s)

  • Strategic direction 1: strategic information for focused action

    Golden Hall

    Day: 1 November

    Time: 13:30

    The Summit’s agenda takes the Global Health Sector Strategy on Viral Hepatitis (GHSS) - and its 5 strategic directions - as its framework. In this plenary session, strategic direction 1 looks at advocacy, political commitment and national planning.

    Chairs: Dr. Leolin Katsidzira, University of Zimbabwe College of Health Sciences and Tatjana Reic, European Liver Patients’ Association

    Presentations:

    • Global viral hepatitis situation and response.

      Dr. Marc Bulterys, World Health Organization

    • WHO country profiles report.

      Prof. Sharon Hutchinson, Glasgow Caledonian University, UK

    • The power of people: integrating civil society in the global hepatitis response.

      Charles Gore, World Hepatitis Alliance

    • The role of liver societies in the global viral hepatitis response.

      Anna Lok, American Association for the Study of Liver Diseases

    • Country level experience of using strategic information to inform their national hepatitis response. 
      Zimbabwe - Rapid assessments: Dr. Leolin Katsidzira, University of Zimbabwe College of Health Sciences
      Vietnam - Hepatitis surveillance: Dr. Tran Dai Quang, Ministry of Health, Viet Nam
    • Q&A session.

    Session objectives:

    To highlight

    • The role and importance of strategic information in planning and monitoring national responses.

    • The priority actions for countries and role of WHO in supporting countries.

    • The latest data on the global viral hepatitis situation and response.

    • Progress made in integrating civil society in the global viral hepatitis response and on global awareness activities.

    • Country examples demonstrating the important role of strategic information for focused action.


  • Policy as a tool for HepC Elimination

    Matisse

    Day: 1 November

    Time: 17:30

    Hepatitis C virus (HCV) infection is considered a major Public Health threat in Europe.

    Hepatitis C virus (HCV) infection is considered a major Public Health threat in Europe. Hepatitis C is a chronic infectious disease with great impact on patients’ morbidity and mortality, with high risk of progression to cirrhosis and liver cancer. In Europe, it is estimated that only 25% of patients with hepatitis C are diagnosed (~14 million people); each year there are 27,000-29,000 newly diagnosed HCV cases in the EU/EEA. Evidence shows that, for some European countries, annual deaths from hepatitis c have quadrupled over the past 20 years. New treatments were recently discovered that cures hepatitis C in up to 97% of cases. This, alongside the devastating effects that the disease can have, means that the paradigm at the community level of hepatitis c treatment should now be elimination.

    Presentations:

    • From policy to action.
      Charles Gore, World Hepatitis Alliance
    • What matters to patients - HepCore.
      Prof. Jeffrey Lazarus, University of Copenhagen
    • Empowering advocates.
      Achim Kautz, Leberhilfe Projekt gUG
    • Modelling for policy change.
      Dr. Homie A. Razavi, Center for Disease Analysis Foundation
    • Brazil strategy and response to HCV.
      Evaldo Stanislau Affonso de Araújo, Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo
    • Let's End HepC Dashboard - assessing and comparing different Countries policies in real-time towards the elimination of HCV until 2030.
      Ricardo Baptista Leite, Member of the Portuguese Parliament and Católica University of Portugal